| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 317.00 | 19.2% |
| Total Income | 317.00 | 19.2% |
| Expenditure | 180.00 | 10.0% |
| PBT | 115.00 | 94.9% |
| Net Profit | 89.00 | 89.4% |
| OPM | 43.22% | 18.41pp |
| NPM | 28.08% | 10.41pp |
| EPS | 0.71 | 86.8% |
Indivior Reports Q1 2026 Revenue $317 Million, Up 19% YoY, Raises Full-Year Guidance
30 Apr 2026 · 30 Apr, 4:33 pm
Summary
Indivior Pharmaceuticals, Inc. reported strong first-quarter 2026 financial results, with total net revenue increasing 19% year-over-year to $317 million. This growth was significantly driven by SUBLOCADE, which saw its net revenue climb 32% to $232 million. The company achieved a record quarterly adjusted EBITDA of $164 million, representing a substantial 112% increase from the prior year. Encouraged by this performance, Indivior raised its full-year 2026 guidance, projecting 13% growth in total SUBLOCADE net revenue and 50% growth in adjusted EBITDA at the midpoint. Management expressed confidence in accelerating SUBLOCADE growth and enhancing profitability while strategically deploying capital.
Key Highlights
- 1
Indivior reported Q1 2026 total net revenue of $317 million, marking a 19% increase year-over-year.
- 2
Total SUBLOCADE net revenue for Q1 2026 grew by 32% year-over-year to $232 million, with U.S. SUBLOCADE net revenue increasing 33% to $218 million.
- 3
GAAP net income for the first quarter of 2026 reached $89 million, while non-GAAP net income was $123 million.
- 4
Adjusted EBITDA for Q1 2026 surged by 112% year-over-year to a record quarterly high of $164 million.
- 5
The company repurchased approximately four million shares for $125 million during Q1 2026 as part of its capital deployment strategy.
- 6
Indivior raised its full-year 2026 financial guidance, now expecting total SUBLOCADE net revenue growth of 13% and adjusted EBITDA growth of 50% year-over-year at the midpoint.
- 7
Over 500,000 patients in the U.S. have been prescribed SUBLOCADE since its launch.
Management Comments
Joe Ciaffoni
We are encouraged by our first quarter results, which reflect the progress we are making against Phase II of the Indivior Action Agenda – Accelerate. Year-over-year we accelerated SUBLOCADE net revenue and dispense unit growth and grew adjusted EBITDA and cash at an even faster rate while executing on our capital deployment strategy. We remain focused on accelerating SUBLOCADE dispense unit growth, growing our bottom line at a significantly faster rate, and strategically deploying capital as we earn our way to Phase III of the Indivior Action Agenda – Breakout — which we are on track to enter in the second half of 2026.
Ryan Preblick
Strong SUBLOCADE performance in the first quarter led us to raise our 2026 financial guidance. We now expect 2026 total SUBLOCADE net revenue growth of 13% year-over-year and adjusted EBITDA growth of 50% year-over-year at the midpoint of our guidance ranges. We strengthened our financial position with the completion of a $500 million convertible senior notes offering and returned capital to our shareholders through the opportunistic repurchase of $125 million in shares during the quarter. We are committed to creating long-term shareholder value as we advance the Indivior Action Agenda.
Informational and educational content only. Not investment advice.